Xu D, Li C, Zhang Y, Zhang J. DNA methylation molecular subtypes for prognosis prediction in lung adenocarcinoma.
BMC Pulm Med 2022;
22:133. [PMID:
35392867 PMCID:
PMC8991665 DOI:
10.1186/s12890-022-01924-0]
[Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2021] [Accepted: 03/30/2022] [Indexed: 02/06/2023] Open
Abstract
Aims
Lung cancer is one of the main results in tumor-related mortality. Methylation differences reflect critical biological features of the etiology of LUAD and affect prognosis.
Methods
In the present study, we constructed a prediction prognostic model integrating various DNA methylation used high-throughput omics data for improved prognostic evaluation.
Results
Overall 21,120 methylation sites were identified in the training dataset. Overall, 237 promoter genes were identified by genomic annotation of 205 CpG loci. We used Akakike Information Criteria (AIC) to obtain the validity of data fitting, but to prevent overfitting. After AIC clustering, specific methylation sites of cg19224164 and cg22085335 were left. Prognostic analysis showed a significant difference among the two groups (P = 0.017). In particular, the hypermethylated group had a poor prognosis, suggesting that these methylation sites may be a marker of prognosis.
Conclusion
The model might help in the identification of unknown biomarkers in predicting patient prognosis in LUAD.
Supplementary Information
The online version contains supplementary material available at 10.1186/s12890-022-01924-0.
Collapse